Your email has been successfully added to our mailing list.

×
-0.0198624904507257 -0.0198624904507257 -0.0198624904507257 -0.0198624904507257 -0.0198624904507257 -0.0198624904507257 -0.0198624904507257 -0.0198624904507257
Stock impact report

MorphoSys appoints Jean-Paul Kress as new CEO [Seeking Alpha]

MorphoSys AG - American Depositary Shares (MOR) 
Company Research Source: Seeking Alpha
MorphoSys appoints Jean-Paul Kress as new CEO MorphoSys ( OTCPK:MPSYF announced Dr. Kress will succeed Dr. Simon Moroney, who had announced his decision not to renew his contract as a member of MorphoSys's Management Board in February 2019. Dr. Jean-Paul has held many senior leadership positions in pharmaceutical and biotechnology firms. Most recently, he  served as President and Chief Executive Officer at Syntimmune, now a subsidiary of Alexion Pharmaceuticals. Prior to this, he acted as Executive Vice President and President, International, and Head of Global Therapeutic Operations at Biogen Inc. Show less Read more
Impact Snapshot
Event Time:
MOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MOR alerts
Opt-in for
MOR alerts

from News Quantified
Opt-in for
MOR alerts

from News Quantified